SCHEMBL5224020

SCHEMBL5224020

Cn1cc(C(=O)Cc2cn(C(c3ccccc3)(c3ccccc3)c3ccccc3)cn2)cc1C(=O)c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SIRT2 Q8IXJ6 14/20 0.37
CYP2C9 P11712 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216640 0.84 CYP2C9 (0.41) NPC1RAB9ACYP2C9KMT2AMEN1
SCHEMBL5216688 0.78 HTT (0.36) NPC1RAB9ASIRT2CYP2C9KMT2A
SCHEMBL6954324 0.71 GSK3B (0.54) NPC1RAB9ACYP2C9KMT2AMEN1
SCHEMBL877052 0.71 SIRT2 (0.46) SIRT2
SCHEMBL10944422 0.70 CYP2C9 (0.57) NPC1RAB9ACYP2C9KMT2AMEN1
SCHEMBL6949750 0.70 CYP2C9 (0.43) NPC1RAB9ACYP2C9KMT2AMEN1
Hydrochloric Acid SCHEMBL6955433 0.69 CYP2C9 (0.45) NPC1RAB9ACYP2C9KMT2AMEN1
SCHEMBL5220589 0.69 CYP2C9 (0.40) CYP2C9KMT2AMEN1POLBMAPT
SCHEMBL9239485 0.69 SIRT2 (0.44) SIRT2
SCHEMBL5220582 0.69 CYP2C9 (0.39) CYP2C9KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458386-B1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO MCNEIL PHARM INC (US) 2007-04-18 EP disclosed
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed
US-6897319-B2 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-05-24 US disclosed
EP-1458386-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER Ortho-McNeil Pharmaceutical, Inc. (US) 2004-09-22 EP disclosed
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-25 US disclosed
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-25 US disclosed
WO-2003057219-A1 AROYL PYRROLE HETEROERYL AND METHANOLS USEFUL FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER ORTHO-MCNEIL PHARMACEUTICAL INC. (US) 2003-07-17 WO disclosed
WO-2003057147-A2 USEFUL AROYL PYRROLE HETEROARYL METHANONES AND METHANOLS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148636-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 NPC1 1743/4885RAB9A 1671/4885SIRT2 3654/4885
US-20040058980-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 NPC1 1743/4885RAB9A 1671/4885SIRT2 3654/4885
US-20030181481-A1 Useful aroyl pyrrole heteroaryl methanones and methanols CYP11B2, NLN, CNR2 NPC1 1743/4885RAB9A 1671/4885SIRT2 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.